Cellergy Pharma
Cellergy Pharma develops first-in-class chimeric antigen receptor T cell therapies to treat severe allergic diseases and cancer. CP-010 is in development for treating uncontrolled severe allergic asthma. CP-020 is in development for treating relapsed/refractory acute myeloid leukemia.
Contact Name:
Ronald Dudek
Contact Email:
Website:
https://cellergypharma.com/
City, State – Congressional District:
Wilmington,
DE
–
At-Large
Technology:
Drug
Funding:
Allergy and Infectious Diseases (NIAID)
NIH Projects:
NIH RePorter for
Cellergy Pharma
Sponsored Event(s):
Biotech Showcase | 2025
